Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017, and provided a business update. “The second quarter was marked by validating events in each of the three pillars of our global tivozanib strategy: a recommendation for approval of tivozanib in advanced renal cell carcinoma (RCC)

Download PDF Additional Resources Sufficient to Fund Planned Operations into the 4Q 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 27, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc. (Hercules) and the sale of common stock via its at-the-market issuance sales agreement with FBR & Co. (FBR). Pursuant to its 2010

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 23, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). The CHMP’s recommendation is now referred to the European Commission (EC). The EC, which typically

Download PDF – Pre-planned futility analysis of the trial expected midyear 2017;topline data expected in the first quarter of 2018 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 20, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 8, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in subjects with advanced renal cell carcinoma (RCC) has progressed to the Phase 2 portion of the trial. Advancement of the study into the Phase 2 expansion follows the

Download PDF Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Announces Trial in Progress Poster Also Presented Highlighting Phase 3 TIVO-3 Study of Tivozanib in RCC CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 5, 2017– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc., co-development partners, today announced the presentation of results from

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 19, 2017– AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 16, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017. In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team